Pituitary magnetic resonance imaging abnormalities and 1-year growth response in children with idiopathic growth hormone deficiency Authors: Jaewon Choe, Jieun Lee, Jaehyun Kim Published: 2026 ABSTRACT Purpose Brain magnetic resonance imaging (MRI) is used to assess anatomical abnormalities in children with idiopathic growth hormone deficiency (IGHD), but its prognostic relevance remains uncertain. We investigated whether structural abnormalities on brain MRI are associated with 1-year growth response to recombinant human growth hormone (rhGH) therapy in Korean children with IGHD.Methods This multicenter retrospective study included 457 IGHD patients from the LG Growth Study registry who had baseline brain MRI and received rhGH therapy for ≥1 year. MRI findings were categorized as normal or as showing pituitary or extrapituitary abnormalities. Growth outcomes—change in height SDS (ΔHeight SDS) and height velocity—were compared across groups. Multivariable regression was performed to adjust for clinical variables.Results Among 457 patients, 122 (26.7%) had structural abnormalities on brain MRI, while 335 (73.3%) had normal findings. In unadjusted analysis, those with abnormalities showed slightly lower ΔHeight SDS than those with normal brain MRI (p=0.028). However, subgroup differences were not significant when analyzed categorically. In multivariable regression, younger age at treatment (β=-0.050, p=0.004), higher baseline body mass index SDS (β=0.055, p=0.002), and greater rhGH dose (β=0.806, p=0.039) were significantly associated with greater ΔHeight SDS, while brain MRI abnormalities were not predictive of response.Conclusions While brain MRI is an important diagnostic tool in IGHD for identifying anatomical abnormalities, our findings suggest that such abnormalities, particularly when mild or isolated, have limited utility in predicting short-term growth response to rhGH therapy. Highlights · In 457 Korean children with idiopathic growth hormone deficiency, 26.7% exhibited structural brain magnetic resonance imaging abnormalities, predominantly pituitary hypoplasia. However, these structural findings did not independently predict 1-year growth outcomes following recombinant human growth hormone therapy. Instead, younger age, higher baseline body mass index, and greater recombinant human growth hormone dose were the significant predictors of early height gain. Introduction Growth hormone deficiency (GHD) in children can have heterogeneous causes and presentations across different populations [1,2]. Epidemiological studies from various regions have documented differences in the prevalence and etiologies of GHD [2]. International research efforts, such as the Pfizer International Growth Database (Kabi International Growth Study, KIGS) registry, have proposed classification systems for GHD etiologies [3], and current consensus guidelines recommend including brain magnetic resonance imaging (MRI) as part of the diagnostic work-up for childhood GHD [4]. MRI of the brain (particularly the hypothalamicpituitary [HP] region) is recommended to identify structural lesions that might be associated with GHD. However, most of these studies involved Western populations, leaving a gap in understanding the characteristics and clinical implications of brain MRI findings in Asian cohorts. This study uniquely evaluates a large Korean cohort, providing region-specific data that may complement international findings and inform clinical practice in East Asian populations. GHD is broadly categorized into organic and idiopathic types. Organic GHD is typically caused by identifiable structural or acquired conditions such as brain tumors, cranial irradiation, trauma, or congenital malformations of the HP axis. In contrast, idiopathic GHD (IGHD) lacks a clearly defined etiology despite thorough clinical and radiological evaluation. According to previous epidemiologic studies, organic GHD accounts for approximately 20%–30% of childhood GHD cases, while the majority are classified as idiopathic [4,5]. A substantial minority of these idiopathic cases exhibit abnormalities on brain MRI, such as an ectopic posterior pituitary or a small anterior pituitary gland (pituitary hypoplasia) [6]. These radiological findings may indicate an underlying congenital or structural defect in patients clinically classified as idiopathic. However, whether such brain MRI abnormalities have predictive value for treatment response to growth hormone (GH) therapy remains uncertain. Moreover, the classification of patients with isolated pituitary abnormalities as having idiopathic GHD has been debated. International guidelines, including those by the GH Research Society, permit classifying mild or isolated pituitary anomalies without multiple pituitary hormone deficiencies (MPHDs) as idiopathic [7], but this remains a source of conceptual ambiguity in clinical practice. Some studies have proposed that specific pituitary anomalies may correlate with differential growth outcomes [8] and that patients with distinct structural lesions may have more severe GHD and thereby exhibit varied treatment responses [5,9]. Other studies, however, have reported that children with normal brain MRI scans can respond just as well to GH therapy as those with abnormal scans [5,9]. Despite these insights, no study has specifically examined this question in a Korean pediatric population. We therefore undertook this multicenter retrospective study to evaluate whether structural abnormalities on brain MRI are associated with differences in clinical characteristics or short-term growth response in Korean children with idiopathic GHD. In particular, we aimed to assess the independent prognostic value of MRI findings in predicting growth outcomes following 1 year of GH therapy. Materials and methods 1. Study design and population This retrospective cohort analysis used data from the LG Growth Study (LGS), a multicenter noninterventional registry designed to evaluate the long-term safety and effectiveness of recombinant human GH (rhGH) therapy in Korean children [10,11]. The design and protocol of the LGS have been described in detail elsewhere [10], and the 5-year outcome data have demonstrated its safety and efficacy in real-world clinical practice [11]. The study included 3 daily rhGH products (Eutropin, Eutropin AQ, and Eutropin Pen) and 1 weekly product (Eutropin Plus), all manufactured by LG Chem Ltd. When GH stimulation testing was indicated, appropriate pharmacologic agents—such as insulin-induced hypoglycemia, L-dopa, clonidine, L-arginine, or glucagon— were selected at the discretion of the treating physician. After at least 2 GH stimulation tests (GHSTs), patients with a peak GH level below 10 ng/mL [8] were classified as having GHD in the LGS database. Patients with both GH peaks <5 ng/mL were classified as having complete GHD, while those with at least one GH peak between 5 and 10 ng/mL were classified as partial GHD, in accordance with established diagnostic criteria [12]. We included children diagnosed between February 2001 and February 2020. Idiopathic GHD was defined by the absence of an identifiable organic cause for growth failure and peak GH levels <10 ng/mL on stimulation testing. All patients included in this study had isolated GHD, defined as GH deficiency without concurrent deficiencies in other pituitary hormones, including a normal thyroid axis (thyroid-stimulating hormone and free T4), adrenal axis (morning cortisol or adrenocorticotropic hormone stimulation results when available), and gonadotropin axis (luteinizing hormone/follicle stimulating hormone and sex steroid levels appropriate for age and pubertal status). To focus exclusively on idiopathic cases, we excluded patients with known genetic syndromes, brain tumors, prior cranial irradiation, or other acquired causes of GHD. Of the 3,813 pediatric patients initially enrolled in the LGS, 2,273 were diagnosed with GHD based on investigator assessments. To ensure the validity of clinical and imaging data, we excluded 888 patients without available brain MRI data, 4 with organic GHD, 896 with incomplete height and/or weight measurements, 6 receiving medications known to affect serum glucose levels, 2 with MPHDs, 4 with missing GHST results, and 16 whose bone age (BA) exceeded chronological age (CA) (BA > CA) (Fig. 1). A total of 457 patients met the inclusion criteria and were included in the final analysis. Of these, 132 (28.9%) were classified as having complete GHD and 325 (71.1%) as partial GHD. 2. MRI classification In the LGS registry, brain MRI information became more consistently available after 2018 as the data collection process was standardized. Brain MRI findings were obtained according to the study protocol and categorized as either normal or abnormal. Abnormalities included intrinsic defects within the pituitary region—such as ectopic posterior pituitary, an interrupted or thinned pituitary stalk, and anterior pituitary hypoplasia—as well as incidental extrapituitary lesions, including arachnoid cysts or midline cerebral anomalies. Pituitary hypoplasia in the LGS registry was defined based on the local radiologist’s impression of a small anterior pituitary gland. Quantitative pituitary height measurements (e.g., 0.05) (Table 1). Peak GH levels during stimulation testing were also comparable across MRI groups (Table 1), suggesting that structural abnormalities were not preferentially associated with either complete or partial GHD. 3. Growth response to rhGH therapy After 1 year of rhGH treatment, patients showed substantial improvement in height SDS, with a mean increase of 0.77±0.36. Female patients exhibited a greater increase in height SDS compared with males in unadjusted analysis (P=0.038); however, this difference was not significant in multivariable regression analysis (Supplementary Fig. 2). No significant difference in ΔHeight SDS was observed between patients with complete and partial GHD (Supplementary Fig. 3). Similarly, baseline height SDS and 1-year height SDS were comparable across the 3 MRI groups (pituitary, extrapituitary, and normal), with mean ΔHeight SDS values of 0.72, 0.66, and 0.80, respectively (P=0.079) (Table 2; Fig. 2). To further explore the impact of brain MRI classification, we applied multiple grouping strategies, including: (1) normal versus all abnormal findings; (2) normal, pituitary-only, combined pituitary and extrapituitary, and extrapituitary-only groups; (3) normal versus any pituitary involvement versus extrapituitary-only; and (4) normal, pituitary-only, and all others with extrapituitary lesions. Among these, only the first grouping (normal vs. all abnormal) demonstrated a statistically significant difference in ΔHeight SDS (P=0.028), with the abnormal group showing a slightly lower response; however, this difference disappeared after adjusting for clinical covariates. No significant differences were observed with the other grouping strategies. 4. Multivariable regression analysis To further identify predictors of growth response to rhGH therapy, we conducted multivariable linear regression analyses using the change in height SDS (ΔHeight SDS) as the dependent variable (Table 3). Younger age at treatment initiation (β=-0.050, P=0.004), higher BMI SDS at screening (β=0.055, P=0.002), and higher average rhGH dose during treatment (β=0.806, P=0.039) were significantly associated with greater height gain. Higher peak GH levels during stimulation testing showed a modest but significant negative association (β=-0.022, P=0.005), while BA exhibited a nonsignificant inverse trend (P=0.604). Additional results using absolute height SDS at 1 year are provided in Supplementary Table 2. Discussion In this multicenter cohort of Korean children with IGHD, approximately 26.7% showed structural abnormalities on brain MRI, most commonly pituitary hypoplasia. While unadjusted comparisons suggested a significant difference in growth response between the normal and abnormal MRI groups, this association disappeared after adjusting for clinical covariates, consistent with previous reports that such anomalies, although common, do not consistently predict growth response [8,15,16]. Our study extends these findings to a large Korean population, complementing existing Western registry data. Although CA–BA and IGF-1 SDS differed between MRI groups at 1 year, these parameters were not correlated with growth outcomes, suggesting hormonal or maturational variations rather than structural determinants. Jung et al. [17] proposed that serum IGF-I SDS and GH peak levels may help predict brain MRI abnormalities, but such approaches cannot replace direct imaging. Brain MRI remains essential for suspected organic GHD, particularly with low GH peaks or MPHDs [4,18,19]. Guidelines from the GH Research Society [4] and KIGS registry analyses [3,12] allow classification as IGHD when mild or isolated anomalies—such as pituitary hypoplasia—are present without multiple hormone deficiencies. Isolated brain MRI abnormalities may still reflect congenital HP axis defects [20]. Recent quantitative MRI studies [21] suggest that such anomalies could involve myelin alterations and increased vulnerability in GH–IGF-1–related neural networks. An ectopic posterior pituitary or stalk interruption is strongly linked to severe, often multiple deficiencies [5,18]. However, for mild anomalies without additional endocrine deficits, the structure–function relationship remains unclear [9,15]. Interpretation is further complicated by age- and puberty-related changes in pituitary size and interobserver variability [22]. In our study, none of the MRI grouping strategies predicted growth response in regression models. Notably, the extrapituitary group had lower IGF-1 SDS despite similar GH stimulation results, suggesting possible subtle hypothalamic–pituitary dysregulation. Recent reports provide further context for our findings. In a meta-analysis of nonacquired GHD, Hwang et al. [8] summarized 15 observational studies and found that brain MRI abnormalities were present in approximately one-quarter of patients, but their prevalence and clinical implications varied substantially across cohorts. Importantly, MRI findings were not consistently predictive of growth outcomes, echoing our adjusted results. In Korea, Jung et al. [17] reported that pituitary abnormalities were frequent among IGHD patients in a single tertiary center, but these structural findings did not translate into reliable prognostic information for GH treatment response. Similarly, Oh et al. [23] evaluated pituitary volume using quantitative MRI and noted an association with growth response in GHD but not in idiopathic short stature, underscoring the limited generalizability of structural parameters. From a regional perspective, Zhang et al. [24] observed that smaller pituitary height correlated with greater catch-up growth in Chinese children with GHD, suggesting potential ethnic or methodological influences on outcome variability. Collectively, these studies support our conclusion that although structural anomalies are common and sometimes associated with hormonal profiles, they are not independently reliable predictors of short-term growth response once clinical and biochemical covariates are taken into account. Previous studies have yielded mixed results: some show associations between specific anomalies and growth outcomes [6,24-26], whereas others report none [15,16]; large datasets demonstrate wide variability even with similar MRI features [3,8]. This likely reflects the multifactorial nature of GH response, influenced by receptor function, IGF-I bioactivity, genetics, nutrition, adherence, and treatment timing [4,16]. Even with uniform anatomical diagnoses such as stalk interruption, outcomes may differ substantially [18]. Variability in brain MRI acquisition and interpretation across centers represents a major methodological limitation of this study. Because imaging protocols were not standardized and no centralized review was performed, interobserver variability may have influenced the classification of structural abnormalities and could partly explain the absence of a consistent association between MRI findings and growth outcomes. Additional limitations include the 1-year duration of follow-up—which precluded assessment of longer-term outcomes such as near-adult height or pubertal progression—lack of detailed information on rhGH dose adjustments or adherence, and the absence of genetic or GH/IGF-I bioactivity analyses that may affect treatment response. Selection bias is also possible because only 457 of 3,813 enrolled patients had complete MRI and growth data; although excluded patients showed broadly similar baseline characteristics, unmeasured differences cannot be ruled out. With these considerations in mind, our findings suggest that while brain MRI has clear diagnostic value in IGHD, mild or isolated abnormalities should be interpreted cautiously and are unlikely to provide reliable prognostic information regarding short-term growth response. Despite these methodological constraints, this large multicenter cohort highlights that clinical and biochemical factors remain the primary determinants of early treatment outcomes. Future work should examine whether integrating genetic and hormonal profiling with imaging can improve prognostic accuracy [27-29], given reports both structural and functional brain changes in GHD [20,30]. In conclusion, this large multicenter study provides region-specific evidence on brain MRI abnormalities in Korean children with IGHD. Although such findings did not independently predict short-term growth response, they remain important for diagnosis and should be interpreted in conjunction with clinical and biochemical data. Incorporating brain MRI results into a broader clinical context may help guide balanced treatment decisions and optimize patient care.